

ORA

The Globally Recognized Oral Vehicle Product Line Brought to You by Medisca





Developed over 20 years ago by US-based Paddock Laboratories and later acquired by Perrigo and more recently, Padagis, the ORA Product Line is a highly established and globally recognized oral vehicle brand brought to you exclusively by Medisca*.











Product No.	2348	2349	0743	0744	2343	
Appearance	Opaque, pi	nkish liquid	Translucent, milky white, thixotropic liquid	Clear liquid with a slight tint		
Taste	Sweet citrus	-berry flavor	Very bland taste (no sweeteners or flavors)	Sweet citrus-berry flavor		
Application	Ideal for pediatric and	geriatric suspensions	Ideal for pediatric, geriatric, and naso-gastric suspensions	ldeal for pediatric and geriatric suspensions		
Intended Use	Flavored Oral Suspending Vehicle	Flavored Sugar-Free Oral Suspending Vehicle	Oral Suspending Vehicle	Flavored Syrup Vehicle	Sugar-Free, Alcohol-Free Syrup Vehicle	
ph Approximately	4.0 - 4.5	4.0 - 4.5	4.0 - 4.5	4.0 - 4.5	4.0 - 4.5	
Osmolality (mOsmol/kg) Approx.			157	4109	1979	
Dye-Free / Alcohol Free	re-Free / Alcohol Free		Dye-Free	- Alcohol-Free		
Preservative Effectiveness	Passes USP microbial challenge test <51>					

^{*}Excludes United States, Israel, and Australia.



With over 150 stability studies to support its use and strong brand recognition, the ORA line is the most sought after oral vehicle for compounded oral medications with notable impacts on pediatric and geriatric medicine.

View all studies

API	Concentration	Base	BUD & Storage at RF	BUD & Storage at RT	Reference
Amlodipine Besylate	1 mg/mL	Ora-Sweet: Ora-Plus / 1% Methylcellulose: Simple Syrup	91 days at 4°C	56 days at 25°C	Nahata MC, Morosco RS, Hipple TF. Stability of amlodipine besylate in two liquid dosage forms. J American Pharm Assoc. 1999;39(3):375-377 <u>View study</u>
Atenolol	2 mg/mL	Ora-Sweet SF	NA	90 days	Patel D, Doshi DH, Desai A. Short-term stability of atenolol in oral liquid formulations. IJPC. 1997;1(6):437-439 View study
Baclofen	10 mg/ml	Ora-Sweet: Ora Plus / Ora-Sweet SF: Ora Plus	60 days 5°C	60 days 25°C	Allen LV Jr., Erickson MA. Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(18):2179-2184 <u>View study</u>
Diclofenac Sodium	10 mg/ml	Ora Blend	93 days at 3-5°C	93 days at 23-25°C	Donnelly RF, Pascuet E, Ma C, Vaillancourt R. Stability of diclofenac sodium oral suspensions packaged in amber polyvinyl chloride bottles. Can J Hosp Pharm. 2010;63(1):2179-2184 <u>View study</u>
Gabapentin	100 mg/ml	Ora-Sweet: Ora-Plus	91 days at 3-5°C	56 days at 23-25°C	Nahata MC. Development of two stable oral suspensions for gabapentin. Pediatr Neurol. 1999;20(3):195-197 <u>View study</u>
Melatonin	1 mg/mL	Ora-Sweet: Ora Plus / Ora-Sweet SF: Ora Plus	NA	90 days	Johnson CE, Cober MP, Thome T, Rouse E. Stability of an extemporaneous alcohol-free melatonin suspension. Am J Health-Syst Pharm. 2011:68(5):420-423 View study
Metronidazole	50mg/mL	Ora-Sweet: Ora Plus / Ora-Sweet SF: Ora Plus	60 days at 5°C	60 days at 25°C	Allen LV Jr, Erickson MA. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(17):2073-2078 View study
Nifedipine	4 mg/ml	Ora-Sweet: Ora-Plus / 1% Methylcellulose: Simple Syrup	91 days at 4°C	91 days at 25°C	Nahata MC, Morosco R, Willhite EA. Stability of nifedipine in two oral suspensions stored at two temperatures. J Am Pharm Assoc. 2002;42(6):865-867 <u>View study</u>
Tacrolimus	0.5 mg/mL	Ora-Plus: Simple Syrup	NA	56 days	Jacobson PA, Johnson CE, West NJ, Foster JA. Stability of tacrolimus in an extemporaneously compounded oral liquid. Am J Health-Syst Pharm. 1997;54(2):178-180. Elefante A, Muindi J, West K, et al. Long-term stability of a patient-convenient 1 mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels. Bone Marrow Transplantation. 2006;37(8):781-784 View study
Tadalafil	5 mg/ml	Ora-Sweet: Ora Plus	NA	91 days at 23-25°C	Petit RS, Johnson CE, Caruthers RL. Stability of an extemporaneously prepared tadalafil suspension. Am J Health-Syst Pharm. 2012;69:592-4 <u>View study</u>
Tramadol	5 mg/ml	Ora-Sweet SF: Ora-Plus / Ora Plus: Strawberry Syrup	90 days	90 days	Wagner DS, Johnson CE, Cichon-Hensley BK, DeLoach SL. Stability of oral liquid preparations of tramadol in strawberry syrup and a sugar-free vehicle. Am J Health-Syst Pharm. 2003;60(12):1268-1270 <u>View study</u>
Ursodiol	25 mg/mL	Ora-Plus: Orange Syrup	60 days	60 days	Mallett MS, Hagan RL, Peters DA. Stability of ursodiol 25 mg/mL in an extemporaneously prepared oral liquid. Am J Health-Syst Pharm. 1997;54(12):1401-1404 <u>View study</u>
Vancomycin	25 mg/mL	Ora-Sweet: Sterile Water for Injection	75 days at 4°C	26 days at 23°C	Ensom MHH, Decarie D, Lakhani A. Stability of vancomycin 25mg/mL in Ora-Sweet and water in unit-dose cups and plastic bottles at 4°C and 25°C. Can J Hosp Pharm. 2010;63(5):366-372 <u>View study</u>



Versatile, **stable**, **and thoroughly tested**, the ORA product line has vast potential in optimising patient care from simple OTC formulations to critical hospital care.











OTC Pediatric

Geriatric

Veterinary



For questions on the product line, where to start, and formulation possibilities. Scan the QR code with your smartphone to contact the Medisca Compounding Service Team for a complementary call with our Formulation Experts.



